The efficacy of a novel, triple combination in the treatment of MM
Can ibrutinib be used as a first-line treatment in CLL?
Do patients with CLL require CAR T-cell therapy?
Biomarkers for acute myeloid leukemia (AML) – lessons from IL-2 immunotherapy with HDC
KEYNOTE-183 trial of pembrolizumab in multiple myeloma: trial design and rationale